NTRK1 and colorectal neoplasm: Besides synergizing with ICIs, regorafenib may also enhance the radiosensitivity of colorectal tumors by blocking radiation-induced activation of receptor tyrosine kinases, inhibiting VEGF-mediated angiogenesis, and suppressing DNA damage repair (17, 18).